Guanethidine于1959年合成，被认为可以通过干扰神经节后交感神经纤维中的化学递质物质的代谢来降低血压。

Guanethidine sulphate, synthesized in 1959, is thought to lowing blood pressure by interfering with the metabolism of chemical transmitter substances in post-ganglionic sympathetic nerve fibres.

Sympathetic fibers ablation is associated with a loss of rat endothelial cell marker (RECA), but no significant effect of guanethidine was found on the survival of endothelial cells and mesenchymal stem cells in vitro [1].

Guanethidine (30 mg/kg, s.c., 1 h) does not affect IL-18 hypernociception in TNFR1 (-/-) mice as a sympathetic blocker [2]. Animal Model: Wild-type (WT) Balb/c,TNFR1 (-/-) and IFN -γ -γ (-/-) mice [2]. Dosage: 30 mg/kg Administration: Guanethidine (30 mg/kg, s.c., 1 h, diluted in saline) Result: Pre-treatment with guanethidine (sympathetic blocker) unaffected IL-18 hypernociception in TNFR1 (-/-) mice.

55-65-2

C10H22N4

198.31

1-[2-(azocan-1-yl)ethyl]guanidine

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years